Lack of correlation between blood gold concentrations and clinical response in patients with definite or classic rheumatoid arthritis receiving auranofin or gold sodium thiomalate

complications of gold sodium thiomalate therapy in rheumatoid arthritis

to determine the complications of gold sodium thiomalate therapy in rheumatoid arthritis (ra), 32 patients with active ra (27 female, 5 male) treated for a mean period of 28 ? 14 weeks were studied. from these patients, 62.5 (46-79) percent showed at least one drug reaction. pruritus was the most common complication occurred in 59 (42-76) percents, and was accompanied by skin rush in 37 (15-57)...

ADVERSE REACTIONS OF GOLD SODIUM THIOMALATE IN RHEUMATOID ARTHRI TIS PATIENTS IN SOUTHERN IRAN

To confirm the side-effects of gold sodium thiomalate (GSTM), we carried out a retrospective study examining 102 consecutive patients with rheumatoid arthritis attending the Rheumatology Unit of Hafez Hospital, Shiraz, Iran, in whom GSTM was initiated between 1983-1989. Only patients with classical or definite RA (ARA criteria) we(e included in this study. Patients were categorized as havi...

Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy.

Seventy two patients with classical or definite rheumatoid arthritis (RA) were randomly allocated to receive gold or D-penicillamine therapy (DPA) in a prospective study designed to evaluate whether it is possible to predict which patients will show radiological progression despite therapy. Forty five patients completed 12 months' treatment. There were no significant demographic or clinical dif...

Serum IgE concentrations in rheumatoid arthritis: lack of correlation with gold toxicity.

Study of Oral Gold ( Auranofin ) in Treatment of Iranian Patient with Rheumatoid Arthritis (RA). Preliminary Report of 6 Months Treatment

28 patients with classical / definite RA entered to a prospective open study evaluating efficacy and side effects of Auranofin. 21 patients completed 6 months of therapy with 6 mg Auranofin daily. Parameters of disease activity including Joint Tenderness Score, Joint Swelling Score, Walking Time and duration of Morning Stiffness improved significantly after 6 months (p<0.001). Grip strength, Su...